As U.S. regulatory uncertainty swirls around the vaccine space and health care in general, Vaxcyte Inc. stands poised for a ...

The National Vaccine Committee has approved, in principle, the implementation of policies supporting local administrative ...

Immune responses to PCV13 were blunted among infants who received the first vaccine dose during a respiratory viral season.

Taiwan will expand its free pneumococcal vaccination program to include high-risk individuals aged 19 to 64 starting March 10 ...

We recently published a list of the 10 Best Vaccine Stocks to Buy According to Hedge Funds. In this article, we are going to ...

For a community to be protected against contagious diseases, enough residents need to be vaccinated to provide “herd immunity ...

The pneumococcal conjugate vaccine – codenamed PCV21/GBP410 – has started pivotal trials in the prevention of both paediatric Streptococcus pneumoniae, which remains a major public health ...

Around 300 residents in this capital town received free vaccines through the Department of Health’s (DOH) “Big Catch-Up” ...

Research analysts at Leerink Partnrs issued their Q1 2025 earnings per share estimates for Vaxcyte in a research report issued to clients and investors on Tuesday, February 25th. Leerink Partnrs ...

Q4 2024 Earnings Conference Call February 25, 2025 4:30 PM ETCompany ParticipantsAndrew Guggenhime - President and ...

Andrew Guggenhime; President, Chief Financial Officer; Vaxcyte Inc. Grant Pickering; Chief Executive Officer, Co-Founder, Director; Vaxcyte Inc. Jim Wassil; Executiv ...